Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III study of S-1/Oxaliplatin comparing Tegafur-Uracil/Leucovorin in the Adjuvant chemotherapy of Stage IIIb colorectal cancer

Next Previous
X
Search
Trial Profile

Randomized phase III study of S-1/Oxaliplatin comparing Tegafur-Uracil/Leucovorin in the Adjuvant chemotherapy of Stage IIIb colorectal cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Folinic acid; Tegafur/uracil
  • Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTS-CC 02
  • Sponsors Taiho Pharmaceutical Company

    • Most Recent Events

    • 17 Jan 2021 Status changed from active, no longer recruiting to completed, as per Final Results presented at the 2021 Gastrointestinal Cancers Symposium
    • 17 Jan 2021 Primary endpoint has not been met. (Disease-free survival (DFS), as per Results presented at the 2021 Gastrointestinal Cancers Symposium
    • 17 Jan 2021 Final Results presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top